Cigna Corp. plans to expand a system that uses artificial intelligence to identify gaps in treatment of chronic diseases, such as patients skipping their medications, and deliver personalized recommendations for specific patients.
The product, called Health Connect 360, integrates data from a combination of sources and analytical tools, some developed at Cigna and others brought in as part of its $54 billion acquisition of pharmacy-benefit manager Express Scripts Holding Co., completed late last year.
Health Connect 360 was developed for treatment of chronic diseases, including diabetes and heart disease. The system aggregates medical, pharmacy, lab, and biometric data into a dashboard that is accessible through an online interface.
Cigna is already using AI to predict whether patients might abuse or overdose on prescription opioids.
"Across the health-care industry, as with every industry, the incredible growth in data availability and ability to communicate enables new kinds of interventions that were just too cost-prohibitive to even consider before," said Matthew Josefowicz, chief executive of research and advisory firm Novarica Inc.
From The Wall Street Journal
View Full Article – May Require Paid Subscription